Filtered By:
Source: Thrombosis Research
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 219 results found since Jan 2013.
Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency
Stroke is defined as a focal or global disturbance of cerebral function lasting over 24h; resulting from disruption of blood supply [1]. Stroke during pregnancy is fortunately a rare event, but it can have severe consequences, such as long-term disability or death, with 9.5% of all maternal deaths being related to stroke [2]. The overall risk of pregnancy-related stroke was 34.2 (95% CI 33.3–35.1) per 100000 deliveries in the USA, with 48% occurring postpartum, 41% at the time of delivery and 11% antepartum [3].
Source: Thrombosis Research - January 27, 2016 Category: Hematology Authors: Mirjana Kovac, Gorana Mitic, Zeljko Mikovic, Vesna Mandic, Valentina Djordjevic, Laszlo Muszbek, Zsuzsanna Bereczky Tags: Correspondence Source Type: research
NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation
Large elevations of high sensitive Troponin T (hsTnT) in ischemic stroke patients is associated with a poor outcome. In a pilot study we found a high prevalence of malignancies among these patients. Since neutrophil extracellular traps (NETs) have been linked to cancer-associated thrombosis, we hypothesized that the concomitant cerebral and myocardial ischemia could be the result of a NET-induced hypercoagulable state.
Source: Thrombosis Research - January 12, 2016 Category: Hematology Authors: Charlotte Thålin, Melanie Demers, Bo Blomgren, Siu Ling Wong, Magnus von Arbin, Anders von Heijne, Ann Charlotte Laska, Håkan Wallén, Denisa D. Wagner, Sara Aspberg Tags: Full Length Article Source Type: research
Association between rs1801133 polymorphism and risk of adult ischemic stroke: Meta-analysis based on case–control studies
This study is aimed to quantify the strength of the association between rs1801133 polymorphism and ischemic stroke risk.
Source: Thrombosis Research - December 1, 2015 Category: Hematology Authors: Min Chen, Ben Yu Mao, Dan Wang, Xianglin Cheng, Chuan Xin Xu Source Type: research
Thrombophilia testing in young patients with ischemic stroke
The possible significance of thrombophilia in ischemic stroke remains controversial. We aimed to study inherited and acquired thrombophilias as risk factors for ischemic stroke, transient ischemic attack (TIA) and amaurosis fugax in young patients.
Source: Thrombosis Research - November 7, 2015 Category: Hematology Authors: Sidse Høst Pahus, Anette Tarp Hansen, Anne-Mette Hvas Tags: Full Length Article Source Type: research
Prevention and follow-up in thromboembolic ischemic stroke: Do we need to think out of the box?
Stroke is one of the most debilitating thrombotic diseases, and world-wide it is estimated that by, 2030 23 million people will be affected. Except for the impact on the individual families, the world economy is also affected adversely. Although the medical treatment and knowledge of stroke are both increasing and well-researched, we still do not see a light in the tunnel. Currently various diagnostic tests are employed to determine the specific type of ischemic stroke as classified by the TOAST criteria.
Source: Thrombosis Research - November 4, 2015 Category: Hematology Authors: Albe C. Swanepoel, Etheresia Pretorius Tags: Review Article Source Type: research
Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?
Antiplatelet therapy is the cornerstone of secondary prevention against acute thrombotic events in patients with cardiovascular disease [1]. Health Organizations around the world recommend combination therapy with aspirin and a P2Y12 receptor inhibitor for up to one year following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), and lifelong aspirin therapy thereafter [2]. Vorapaxar, a first-in-class novel protease-activated receptor (PAR)-1 antagonist, was approved in addition to standard antiplatelet therapy, to further reduce the risk of myocardial infarction (MI), stroke, cardiovascular dea...
Source: Thrombosis Research - October 30, 2015 Category: Hematology Authors: Marie Lordkipanidzé Source Type: research
N2 extenuates experimental ischemic stroke through platelet aggregation inhibition
Thromboxane A2 (TXA2) can induce the platelet aggregation and lead to thrombosis. This will cause the low-reflow phenomenon after ischemic stroke and aggravate the damage of brain issues. Therefore, it is potential to develop the drugs inhibiting TXA2 pathway to treat cerebral ischemia.
Source: Thrombosis Research - October 29, 2015 Category: Hematology Authors: Lijian Yang, Xi Chen, Siqi Wang, Yuxiang Fei, Ding Wang, Yunman Li, Guangwei He, Qiang Wu, Shaoxing Chu, Weirong Fang Source Type: research
An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes
Myocardial infarction and stroke are two of the leading causes of death and disability worldwide [1,2]. Using a combination of aspirin and a platelet P2Y12 antagonist, several large clinical trials have definitively demonstrated the efficacy of dual antiplatelet therapies in preventing myocardial infarction, stroke or death in patients with acute coronary syndromes [3–8]. Dual antiplatelet therapy with aspirin and a thienopyridine-based P2Y12 antagonist (clopidogrel or prasugrel) has now become the standard of care of patients with acute coronary syndromes.
Source: Thrombosis Research - October 16, 2015 Category: Hematology Authors: Frederick A. Ofosu Source Type: research
assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome
No study has examined how the relationship between polycystic ovary syndrome (PCOS) and atherosclerotic cardiovascular diseases (aCVD), of ischemic stroke (ISCH), acute myocardial infarction (AMI), and peripheral vascular disease (PAD), differ in the presence of venous thromboembolism (VTE).
Source: Thrombosis Research - October 13, 2015 Category: Hematology Authors: Ekwutosi M. Okoroh, Sheree L. Boulet, Mary G. George, W. Craig Hooper Tags: Full Length Article Source Type: research
Prasugrel reduces ischaemic infarct volume and ameliorates neurological deficits in a non-human primate model of middle cerebral artery thrombosis
Several clinical trials have demonstrated the benefits of thienopyridine monotherapy in ischaemic stroke patients. Non-human primate models of ischaemic stroke have been used for various antithrombotic agents; however, to the best of our knowledge, there is no data on the effects of P2Y12 antagonists in models, such as the thrombotic middle cerebral artery occlusion (MCAO) monkey model. Accordingly, it remains unclear what level of inhibition of platelet aggregation (IPA) is required for optimal treatment of ischaemic stroke.
Source: Thrombosis Research - September 11, 2015 Category: Hematology Authors: Atsuyuki Tomizawa, Kousaku Ohno, Joseph A. Jakubowski, Makoto Mizuno, Atsuhiro Sugidachi Source Type: research
HAS-BLED score predicts risk of in-hospital major bleeding in patients with acute non-ST segment elevation myocardial infarction
In this study, we compared the HAS-BLED score with the Can Rapid Risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) and Acute Catheterization and Urgent Intervention Triage strategY and the Harmonizing Outcomes with RevascularIZatiON and Stents in acute myocardial infarction (ACUITY-HORIZONS) bleeding risk scores for in-hospital major bleeding risk stratification in NSTEMI patients.
Source: Thrombosis Research - August 28, 2015 Category: Hematology Authors: Ming-Jer Hsieh, Chun-Chieh Wang, Chun-Chi Chen, Chun-Li Wang, Lung-Sheng Wu, I-Chang Hsieh Source Type: research
Warfarin non-persistence among stroke patients with atrial fibrillation
Warfarin treatment discontinuation is significant among patients with atrial fibrillation (AF). For AF patients with stroke a warfarin persistence rate of 0.45 after 2years has previously been reported. No consistent predictors for discontinuation have been established.
Source: Thrombosis Research - July 30, 2015 Category: Hematology Authors: Fredrik Björck, Henrik Renlund, Peter J. Svensson, Anders Själander Tags: Full length article Source Type: research
Warfarin persistence among stroke patients with atrial fibrillation
Warfarin treatment discontinuation is significant among patients with atrial fibrillation (AF). For AF patients with stroke a warfarin persistence rate of 0.45 after 2years has previously been reported. No consistent predictors for discontinuation have been established.
Source: Thrombosis Research - July 30, 2015 Category: Hematology Authors: Fredrik Björck, Henrik Renlund, Peter J. Svensson, Anders Själander Tags: Full Length Article Source Type: research
Self-Reported Adherence to Anticoagulation and Its Determinants Using the Morisky Medication Adherence Scale
Direct oral anticoagulants (DOACs) are used for treatment of venous thromboembolism (VTE) and stroke prevention in atrial fibrillation (AF). Given the shorter half-life and lack of laboratory monitoring compared to vitamin-K antagonists (VKAs), adequate adherence to DOACs is important. Reported anticoagulation adherence is unclear in clinical practice.
Source: Thrombosis Research - July 13, 2015 Category: Hematology Authors: Lana A. Castellucci, Joseph Shaw, Katrien van der Salm, Petra Erkens, Gregoire Le Gal, William Petrcich, Marc Carrier Source Type: research
A new method to quantify β-antithrombin glycoform in plasma reveals increased levels during the acute stroke event
β-antithrombin, the minor antithrombin glycoform in plasma, is probably the major thrombin inhibitor in vivo because of its high heparin affinity. The levels and variability of this glycoform in general population and its relevance in thromboembolic diseases is unknown since there is no specific method to measure this glycoform in clinical samples.
Source: Thrombosis Research - July 6, 2015 Category: Hematology Authors: M.E. de la Morena-Barrio, A. García, I. Martínez-Martínez, A. Miñano, J. Padilla, J. Navarro-Fernández, V. Roldán, S. Águila, J.A. Iniesta, J. Corral, V. Vicente Source Type: research
